Acute administration of oxycodone, alcohol, and their combination on simulated driving—preliminary outcomes in healthy adults
Rationale Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available. Objectives The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone a...
Saved in:
| Published in | Psychopharmacology Vol. 238; no. 2; pp. 539 - 549 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2021
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Rationale
Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available.
Objectives
The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance.
Methods
Healthy participants (
n
= 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration.
Results
Oxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (
p
> 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (
p
< 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (
p
< 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects.
Conclusions
These preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. |
|---|---|
| AbstractList | Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available.
The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance.
Healthy participants (n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration.
Oxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects.
These preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. RationaleEpidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available.ObjectivesThe primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance.MethodsHealthy participants (n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration.ResultsOxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects.ConclusionsThese preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. Rationale Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available. Objectives The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance. Methods Healthy participants ( n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration. Results Oxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo ( p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment ( p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) ( p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects. Conclusions These preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. Rationale Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available. Objectives The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance. Methods Healthy participants (n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration. Results Oxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects. Conclusions These preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available. The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance. Healthy participants (n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration. Oxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects. These preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available.RATIONALEEpidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited controlled data available.The primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance.OBJECTIVESThe primary aim of this study was to assess the effects of a therapeutic dose range of oxycodone alone and in combination with alcohol on simulated driving performance.Healthy participants (n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration.METHODSHealthy participants (n = 10) completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Six 7-h sessions were completed during which oxycodone (0, 5, 10 mg, p.o.) was administered 30 min before alcohol (0, 0.8 g/kg (15% less for women), p.o.) for a total of 6 test conditions. Driving assessments and participant-, observer-rated, psychomotor and physiological measures were collected in regular intervals before and after drug administration.Oxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects.RESULTSOxycodone alone (5, 10 mg) did not produce any changes in driving outcomes or psychomotor task performance, relative to placebo (p > 0.05); however, 10 mg oxycodone produced increases in an array of subjective ratings, including sedation and impairment (p < 0.05). Alcohol alone produced driving impairment (e.g., decreased lateral control) (p < 0.05); however, oxycodone did not potentiate alcohol-related driving or subjective effects.These preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk.CONCLUSIONSThese preliminary data suggest that acute doses of oxycodone (5, 10 mg) do not significantly impair acuity on laboratory-based simulated driving models; however, 10 mg oxycodone produced increases in self-reported outcomes that are not compatible with safe driving behavior (e.g., sedation, impairment). Additional controlled research is needed to determine how opioid misuse (higher doses; parenteral routes of administration) impacts driving risk. |
| Audience | Academic |
| Author | Sloan, Paul A. Lofwall, Michelle R. Fanucchi, Laura C. Walsh, Sharon L. Babalonis, Shanna Coe, Marion A. Nuzzo, Paul A. Ali, Nur |
| AuthorAffiliation | 2 Center on Drug and Alcohol Research, University of Kentucky, College of Medicine, Lexington, KY 5 Department of Psychiatry, University of Kentucky, College of Medicine, Lexington, KY 6 Department of Internal Medicine, University of Kentucky, College of Medicine, Lexington, KY 3 Department of Pharmacology, University of Kentucky, College of Medicine, Lexington, KY 4 Department of Anesthesiology, University of Kentucky, College of Medicine, Lexington, KY 1 Department of Behavioral Science, University of Kentucky, College of Medicine, Lexington, KY |
| AuthorAffiliation_xml | – name: 4 Department of Anesthesiology, University of Kentucky, College of Medicine, Lexington, KY – name: 6 Department of Internal Medicine, University of Kentucky, College of Medicine, Lexington, KY – name: 1 Department of Behavioral Science, University of Kentucky, College of Medicine, Lexington, KY – name: 3 Department of Pharmacology, University of Kentucky, College of Medicine, Lexington, KY – name: 5 Department of Psychiatry, University of Kentucky, College of Medicine, Lexington, KY – name: 2 Center on Drug and Alcohol Research, University of Kentucky, College of Medicine, Lexington, KY |
| Author_xml | – sequence: 1 givenname: Shanna orcidid: 0000-0002-1450-2621 surname: Babalonis fullname: Babalonis, Shanna email: babalonis@uky.edu organization: Department of Behavioral Science, University of Kentucky, College of Medicine, Center on Drug and Alcohol Research, University of Kentucky, College of Medicine – sequence: 2 givenname: Marion A. surname: Coe fullname: Coe, Marion A. organization: Center on Drug and Alcohol Research, University of Kentucky, College of Medicine, Department of Pharmacology, University of Kentucky, College of Medicine – sequence: 3 givenname: Paul A. surname: Nuzzo fullname: Nuzzo, Paul A. organization: Center on Drug and Alcohol Research, University of Kentucky, College of Medicine – sequence: 4 givenname: Michelle R. surname: Lofwall fullname: Lofwall, Michelle R. organization: Department of Behavioral Science, University of Kentucky, College of Medicine, Center on Drug and Alcohol Research, University of Kentucky, College of Medicine, Department of Psychiatry, University of Kentucky, College of Medicine – sequence: 5 givenname: Nur surname: Ali fullname: Ali, Nur organization: Center on Drug and Alcohol Research, University of Kentucky, College of Medicine – sequence: 6 givenname: Paul A. surname: Sloan fullname: Sloan, Paul A. organization: Department of Anesthesiology, University of Kentucky, College of Medicine – sequence: 7 givenname: Laura C. surname: Fanucchi fullname: Fanucchi, Laura C. organization: Center on Drug and Alcohol Research, University of Kentucky, College of Medicine, Department of Internal Medicine, University of Kentucky, College of Medicine – sequence: 8 givenname: Sharon L. surname: Walsh fullname: Walsh, Sharon L. organization: Department of Behavioral Science, University of Kentucky, College of Medicine, Center on Drug and Alcohol Research, University of Kentucky, College of Medicine, Department of Pharmacology, University of Kentucky, College of Medicine, Department of Psychiatry, University of Kentucky, College of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33169203$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstuEzEUhi1URNPCC7BAltiwYIqvc9kgRVW5SJXYwNpybE_iymMHe6YlK3iIPiFPwkmTFlqh2gtb9vf_x8fnHKGDmKJD6CUlJ5SQ5l0hhFFeEUYqIhvCqqsnaEYFZxUjDTtAM0I4rziV7SE6KuWCwBCteIYOOad1xwifoZ9zM40Oazv46MuY9ehTxKnH6cfGJAsB32IdTFqlAJto8bhyPmOThoWPezji4ocp6NFZbLO_9HH5-9f1OrvgwVXnDU7TCApXsI945XQYVxsIOYWxPEdPex2Ke7Ffj9G3D2dfTz9V518-fj6dn1dGCjpWXb-wQvdGcld3XAhaC2Mlqyk3faMNs41hnHZw6wjVXceNMMJ2i1pYTUjb8mP0fue7nhaDs8ZFyDWodfYDPFAl7dX9m-hXapkuVdNKKWsGBm_2Bjl9n1wZ1eCLcSHo6NJUFBOy40DWAtDXD9CLNOUI6QHVQtFkDS-8o5Y6OOVjnyCu2ZqqeS2paCSl27An_6FgWjd4A-XpPZzfE7z6N9G7DG9LDkC7A0xOpWTXK-PHm0qCsw-KErXtLrXrLgXdpW66S12BlD2Q3ro_KuI7UQE4Ll3--xuPqP4AO9_kjg |
| CitedBy_id | crossref_primary_10_1155_2022_6153279 crossref_primary_10_1016_j_rehab_2024_101850 crossref_primary_10_1016_j_drugalcdep_2023_110919 crossref_primary_10_1097_j_pain_0000000000002790 crossref_primary_10_1016_j_fsisyn_2022_100303 |
| Cites_doi | 10.1002/cpt1974154368 10.1002/jcph.557 10.1177/0269216317746583 10.1016/j.biopsych.2013.08.001 10.1080/15389588.2017.1326595 10.1016/j.drugalcdep.2019.107630 10.1002/hup.2394 10.1016/S0885-3924(99)00158-X 10.1016/j.aap.2017.03.001 10.1016/j.sbspro.2012.06.1259 10.2105/AJPH.2017.303902 10.1080/15389588.2017.1378814 10.1016/j.aap.2016.01.001 10.2147/DDDT.S77978 10.1007/s00213-011-2349-6 10.1097/JCP.0000000000001101 10.1016/j.drugalcdep.2003.08.002 10.1001/jamanetworkopen.2020.2361 10.1016/j.amepre.2019.02.025 10.1007/s00213-013-3147-0 10.1016/j.ejpain.2010.09.008 10.1016/j.aap.2017.10.004 10.1016/j.drugalcdep.2012.09.018 10.1111/bcp.13818 10.1001/archgenpsychiatry.2011.26 10.1016/j.ejpain.2004.05.010 10.1016/j.drugalcdep.2008.05.007 10.1111/j.1530-0277.1993.tb00739.x 10.1001/jamanetworkopen.2018.8081 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2020 COPYRIGHT 2021 Springer Springer-Verlag GmbH Germany, part of Springer Nature 2020. |
| Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020 – notice: COPYRIGHT 2021 Springer – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PSYQQ Q9U 7X8 5PM |
| DOI | 10.1007/s00213-020-05702-w |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Psychology Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-2072 |
| EndPage | 549 |
| ExternalDocumentID | PMC7855562 A651475112 33169203 10_1007_s00213_020_05702_w |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: National Institute on Drug Abuse grantid: R56 DA036635 funderid: http://dx.doi.org/10.13039/100000026 – fundername: National Center for Advancing Translational Sciences grantid: KL2 TR000116-04; UL1TR001998 funderid: http://dx.doi.org/10.13039/100006108 – fundername: NCATS NIH HHS grantid: KL2 TR000116-04 – fundername: NCATS NIH HHS grantid: UL1TR001998 – fundername: NCATS NIH HHS grantid: KL2 TR000116 – fundername: NCATS NIH HHS grantid: UL1 TR001998 – fundername: NIDA NIH HHS grantid: R56 DA036635 |
| GroupedDBID | -4W -BR .55 3SX 40D 40E 95. 95~ ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS KOW N2Q R9- RHV SBY SOJ X7M ~EX AAYXX CITATION --- -Y2 .86 .GJ .VR 04C 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2QV 2VQ 2~H 30V 36B 3O- 4.4 406 408 409 53G 5QI 5RE 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDBE ABDBF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTAH ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACNCT ACOKC ACOMO ACPIV ACPRK ACUHS ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AYFIA AZFZN AZQEC B-. B0M BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 DWQXO DXH EAD EAP EBC EBD EBLON EBS ECM EIF EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPAXT EPL EPS ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICJ IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M2M M4Y MA- MK0 N9A NAPCQ NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF- PHGZT PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TN5 TSG TSK TSV TUC TUS U2A U9L UAP UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WIP WJK WK6 WK8 WOW XOL YLTOR YQJ YYP Z45 ZGI ZMTXR ZOVNA ZY4 ~8M 3V. 7QG 7QR 7TK 7XB 8FD 8FK FR3 K9. P64 PHGZM PJZUB PKEHL PPXIY PQEST PQUKI Q9U 7X8 ABBRH ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AFOHR AHWEU AIXLP ATHPR 5PM |
| ID | FETCH-LOGICAL-c541t-9fbd4afc53e69344164cd52613cf7ac2d7c23193e6e01a993c4c4d9b64da00883 |
| IEDL.DBID | 7X7 |
| ISSN | 0033-3158 1432-2072 |
| IngestDate | Thu Aug 21 18:17:17 EDT 2025 Mon Jul 21 11:21:53 EDT 2025 Sat Aug 16 15:32:14 EDT 2025 Wed Mar 19 00:39:02 EDT 2025 Sat Mar 08 18:06:27 EST 2025 Thu Apr 03 07:06:25 EDT 2025 Tue Jul 01 04:16:57 EDT 2025 Thu Apr 24 23:03:26 EDT 2025 Fri Feb 21 02:48:45 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Human Drugged driving Driving simulator Ethanol Oxycodone Impairment Opioid Alcohol |
| Language | English |
| License | Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-9fbd4afc53e69344164cd52613cf7ac2d7c23193e6e01a993c4c4d9b64da00883 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-1450-2621 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7855562 |
| PMID | 33169203 |
| PQID | 2480025699 |
| PQPubID | 47309 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7855562 proquest_miscellaneous_2459355664 proquest_journals_2480025699 gale_infotracmisc_A651475112 gale_infotracacademiconefile_A651475112 pubmed_primary_33169203 crossref_citationtrail_10_1007_s00213_020_05702_w crossref_primary_10_1007_s00213_020_05702_w springer_journals_10_1007_s00213_020_05702_w |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-01 |
| PublicationDateYYYYMMDD | 2021-02-01 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Psychopharmacology |
| PublicationTitleAbbrev | Psychopharmacology |
| PublicationTitleAlternate | Psychopharmacology (Berl) |
| PublicationYear | 2021 |
| Publisher | Springer Berlin Heidelberg Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer – name: Springer Nature B.V |
| References | YadavAKVelagaNRLaboratory analysis of driving behavior and self-perceived physiological impairment at 0.03%, 0.05% and 0.08% blood alcohol concentrationsDrug Alcohol Depend20192051076301:CAS:528:DC%2BC1MXitVSqtLfK10.1016/j.drugalcdep.2019.107630 BernhoftIMHelsTLyckegaardAHouwingSVerstraeteAGPrevalence and risk of injury in Europe by driving with alcohol, illicit drugs and medicinesProcedia Soc Behav Sci2012482907291610.1016/j.sbspro.2012.06.1259 HayleyACDowneyLAGreenMShiferawBKenneallyMKeaneMAdamsMShehabiYDriving simulator performance after administration of analgesic doses of ketamine with dexmedetomidine or fentanylJ Clin Psychopharmacol2019394464541:CAS:528:DC%2BC1MXhvFWlurnJ10.1097/JCP.0000000000001101 KingACde WitHMcNamaraPJCaoDRewarding, stimulant, and sedative alcohol responses and relationship to future binge drinkingArch Gen Psychiatry20116838939910.1001/archgenpsychiatry.2011.26 ZacnyJPGutierrezSSubjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteersPsychopharmacology (Berl)20112184714811:CAS:528:DC%2BC3MXmtlelsLk%3D10.1007/s00213-011-2349-6 StrandMCArnestadMFjeldBMorlandJAcute impairing effects of morphine related to driving: a systematic review of experimental studies to define blood morphine concentrations related to impairment in opioid-naive subjectsTraffic Inj Prev20171878879410.1080/15389588.2017.1326595 JongenSVuurmanEFRamaekersJGVermeerenAThe sensitivity of laboratory tests assessing driving related skills to dose-related impairment of alcohol: a literature reviewAccid Anal Prev20168931481:STN:280:DC%2BC28njt12jtw%3D%3D10.1016/j.aap.2016.01.001 National Survey on Drug Use and Health, Center for Behavioral Health Statistics and Quality. Results from the 2018 National Survey on Drug Use and Health: detailed tables. Rockville (MD): SAMHSA; 2019. https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables NilsenHKLandroNIKaasaSJenssenGDFayersPBorchgrevinkPCDriving functions in a video simulator in chronic non-malignant pain patients using and not using codeineEur J Pain2011154094151:CAS:528:DC%2BC3MXksFelsLs%3D10.1016/j.ejpain.2010.09.008 LinnoilaMHakkinenSEffects of diazepam and codeine, alone and in combination with alcohol, on simulated drivingClin Pharmacol Ther1974153683731:STN:280:DyaE2c7ktVeltQ%3D%3D10.1002/cpt1974154368 BrownTLMilavetzGGaffneyGSpurginAEvaluating drugged driving: effects of exemplar pain and anxiety medicationsTraffic Inj Prev201819S97S10310.1080/15389588.2017.1378814 GalskiTWilliamsJBEhleHTEffects of opioids on driving abilityJ Pain Symptom Manage2000192002081:STN:280:DC%2BD3c3isF2isw%3D%3D10.1016/S0885-3924(99)00158-X WalshSLNuzzoPALofwallMRHoltmanJRJrThe relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusersDrug Alcohol Depend2008981912021:CAS:528:DC%2BD1cXht1Sitr7O10.1016/j.drugalcdep.2008.05.007 ChihuriSLiGUse of prescription opioids and motor vehicle crashes: a meta analysisAccid Anal Prev201710912313110.1016/j.aap.2017.10.004 KressHGKraftBOpioid medication and driving abilityEur J Pain200591411441:CAS:528:DC%2BD2MXhslWrs74%3D10.1016/j.ejpain.2004.05.010 SetnikBSokolowskaMJohnsonFOldenhofJRomachMEvaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participantsHum Psychopharmacol2014292512651:CAS:528:DC%2BC2cXmsVGks7k%3D10.1002/hup.2394 ChihuriSLiGTrends in prescription opioids detected in fatally injured drivers in 6 US states: 1995-2015Am J Public Health20171071487149210.2105/AJPH.2017.303902 KingACCaoDde WitHO’ConnorSJHasinDSThe role of alcohol response phenotypes in the risk for alcohol use disorderBr J Psych20195e38131:CAS:528:DC%2BC1MXisVaiur7J StrandMCVindenesVGjerdeHMorlandJGRamaekersJGA clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteersBr J Clin Pharmacol2019854424531:CAS:528:DC%2BC1MXhsFymsb8%3D10.1111/bcp.13818 ChihuriSLiGUse of prescription opioids and initiation of fatal 2-vehicle crashesJAMA Netw Open20192e18808110.1001/jamanetworkopen.2018.8081 RushCRPretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humansAlcohol Clin Exp Res2001259171:CAS:528:DC%2BD3MXjtFGmur0%3D11198720 BabalonisSHampsonAJLofwallMRNuzzoPAWalshSLQuinine as a potential tracer for medication adherence: a pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humansJ Clin Pharmacol20155512133213431:CAS:528:DC%2BC2MXhvVyiurbI10.1002/jcph.557 MartinCSEarleywineMMustyREPerrineMWSwiftRMDevelopment and validation of the biphasic alcohol effects scaleAlcohol Clin Exp Res19931711401461:STN:280:DyaK3s7pvV2muw%3D%3D10.1111/j.1530-0277.1993.tb00739.x ToriMELarochelleMRNaimiTSAlcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017JAMA Netw Open20203e20236110.1001/jamanetworkopen.2020.2361 LaceyJHKelley-BakerTBerningARomanoERamirezAYaoJMooreCBrainardKCarrKPellKComptonRDrug and alcohol crash risk: a case-control study (Report No. DOT HS 812 355)2016Washington, DCNational Highway Traffic Safety Administration IrwinCIudakhinaEDesbrowBMcCartneyDEffects of acute alcohol consumption on measures of simulated driving: a systematic review and meta-analysisAccid Anal Prev201710224826610.1016/j.aap.2017.03.001 BabalonisSLofwallMRNuzzoPASiegelAJWalshSLAbuse liability and reinforcing efficacy of oral tramadol in humansDrug Alcohol Depend20131291-21161241:CAS:528:DC%2BC38XhsFKnsLzE10.1016/j.drugalcdep.2012.09.018 BerningAComptonRWochingerKResults of the 2013–2014 National Roadside Survey of alcohol and drug use by drivers. Traffic Safety Facts Research Note. Report No. DOT HS 812 1182015Washington, DCNational Highway Traffic Safety Administration MiceliLBednarovaRRizzardoASamoginVDella RoccaGDevelopment of a test for recording both visual and auditory reaction times, potentially useful for future studies in patients on opioids therapyDrug Des Devel Ther201598171:CAS:528:DC%2BC1cXlsVOhsbw%3D10.2147/DDDT.S77978 American Pain Society. Pain management and dosing guide. 2016. http://americanpainsociety.org/uploads/education/PAMI_Pain_Mangement_and_Dosing_Guide_02282017.pdf HedlundJMacekKDrug-impaired driving: marijuana and opioids raise critical issues for states2018Washington, DCGovernor’s Highway Safety Associationhttps://www.ghsa.org/resources/DUID18 KingACMcNamaraPJHasinDSCaoDAlcohol challenge responses predict future alcohol use disorder symptoms: a 6-year prospective studyBiol Psychiatry20147579880610.1016/j.biopsych.2013.08.001 EsserMBGuyGPJrZhangKBrewerRDBinge drinking and prescription opioid misuse in the US, 2012–2014Am J Prev Med20195719720810.1016/j.amepre.2019.02.025 FerreiraDHBolandJWPhillipsJLLamLCurrowDCThe impact of therapeutic opioid agonists on driving-related psychomotor skills assessed by a driving simulator or an on-road driving task: a systematic reviewPalliat Med20183278680310.1177/0269216317746583 FraserHFVan HornGDMartinWRWolbachABIsbellHMethods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) A short-term “direct” addiction testJ Pharmacol Exp Ther19611333713871:CAS:528:DyaF3MXhsVGltL4%3D13701509 KirkpatrickMGde WitHIn the company of others: social factors alter acute alcohol effectsPsychopharmacology (Berl)20132302152261:CAS:528:DC%2BC3sXot1Ojt70%3D10.1007/s00213-013-3147-0 LenneMGDietzePRumboldGRRedmanJRTriggsTJThe effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated drivingDrug Alcohol Depend2003722712781:CAS:528:DC%2BD3sXpt1ektr8%3D10.1016/j.drugalcdep.2003.08.002 National Center for Statistics and AnalysisAlcohol-impaired driving: 2018 data (Traffic Safety Facts. Report No. DOT HS 812 864)2019Washington, DCNational Highway Traffic Safety Administration S Chihuri (5702_CR9) 2019; 2 National Center for Statistics and Analysis (5702_CR28) 2019 MG Lenne (5702_CR24) 2003; 72 DH Ferreira (5702_CR11) 2018; 32 AK Yadav (5702_CR37) 2019; 205 L Miceli (5702_CR27) 2015; 9 S Chihuri (5702_CR8) 2017; 107 HG Kress (5702_CR22) 2005; 9 MC Strand (5702_CR34) 2019; 85 J Hedlund (5702_CR15) 2018 MG Kirkpatrick (5702_CR21) 2013; 230 AC King (5702_CR20) 2019; 5 JH Lacey (5702_CR23) 2016 AC Hayley (5702_CR14) 2019; 39 5702_CR29 IM Bernhoft (5702_CR4) 2012; 48 ME Tori (5702_CR35) 2020; 3 MB Esser (5702_CR10) 2019; 57 S Jongen (5702_CR17) 2016; 89 MC Strand (5702_CR33) 2017; 18 M Linnoila (5702_CR25) 1974; 15 AC King (5702_CR18) 2011; 68 S Babalonis (5702_CR2) 2013; 129 HF Fraser (5702_CR12) 1961; 133 S Babalonis (5702_CR3) 2015; 55 T Galski (5702_CR13) 2000; 19 HK Nilsen (5702_CR30) 2011; 15 B Setnik (5702_CR32) 2014; 29 5702_CR1 CS Martin (5702_CR26) 1993; 17 S Chihuri (5702_CR7) 2017; 109 AC King (5702_CR19) 2014; 75 CR Rush (5702_CR31) 2001; 25 SL Walsh (5702_CR36) 2008; 98 TL Brown (5702_CR6) 2018; 19 A Berning (5702_CR5) 2015 JP Zacny (5702_CR38) 2011; 218 C Irwin (5702_CR16) 2017; 102 |
| References_xml | – reference: GalskiTWilliamsJBEhleHTEffects of opioids on driving abilityJ Pain Symptom Manage2000192002081:STN:280:DC%2BD3c3isF2isw%3D%3D10.1016/S0885-3924(99)00158-X – reference: StrandMCVindenesVGjerdeHMorlandJGRamaekersJGA clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteersBr J Clin Pharmacol2019854424531:CAS:528:DC%2BC1MXhsFymsb8%3D10.1111/bcp.13818 – reference: BrownTLMilavetzGGaffneyGSpurginAEvaluating drugged driving: effects of exemplar pain and anxiety medicationsTraffic Inj Prev201819S97S10310.1080/15389588.2017.1378814 – reference: FerreiraDHBolandJWPhillipsJLLamLCurrowDCThe impact of therapeutic opioid agonists on driving-related psychomotor skills assessed by a driving simulator or an on-road driving task: a systematic reviewPalliat Med20183278680310.1177/0269216317746583 – reference: NilsenHKLandroNIKaasaSJenssenGDFayersPBorchgrevinkPCDriving functions in a video simulator in chronic non-malignant pain patients using and not using codeineEur J Pain2011154094151:CAS:528:DC%2BC3MXksFelsLs%3D10.1016/j.ejpain.2010.09.008 – reference: EsserMBGuyGPJrZhangKBrewerRDBinge drinking and prescription opioid misuse in the US, 2012–2014Am J Prev Med20195719720810.1016/j.amepre.2019.02.025 – reference: WalshSLNuzzoPALofwallMRHoltmanJRJrThe relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusersDrug Alcohol Depend2008981912021:CAS:528:DC%2BD1cXht1Sitr7O10.1016/j.drugalcdep.2008.05.007 – reference: BabalonisSHampsonAJLofwallMRNuzzoPAWalshSLQuinine as a potential tracer for medication adherence: a pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humansJ Clin Pharmacol20155512133213431:CAS:528:DC%2BC2MXhvVyiurbI10.1002/jcph.557 – reference: FraserHFVan HornGDMartinWRWolbachABIsbellHMethods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) A short-term “direct” addiction testJ Pharmacol Exp Ther19611333713871:CAS:528:DyaF3MXhsVGltL4%3D13701509 – reference: JongenSVuurmanEFRamaekersJGVermeerenAThe sensitivity of laboratory tests assessing driving related skills to dose-related impairment of alcohol: a literature reviewAccid Anal Prev20168931481:STN:280:DC%2BC28njt12jtw%3D%3D10.1016/j.aap.2016.01.001 – reference: MiceliLBednarovaRRizzardoASamoginVDella RoccaGDevelopment of a test for recording both visual and auditory reaction times, potentially useful for future studies in patients on opioids therapyDrug Des Devel Ther201598171:CAS:528:DC%2BC1cXlsVOhsbw%3D10.2147/DDDT.S77978 – reference: National Survey on Drug Use and Health, Center for Behavioral Health Statistics and Quality. Results from the 2018 National Survey on Drug Use and Health: detailed tables. Rockville (MD): SAMHSA; 2019. https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables – reference: KressHGKraftBOpioid medication and driving abilityEur J Pain200591411441:CAS:528:DC%2BD2MXhslWrs74%3D10.1016/j.ejpain.2004.05.010 – reference: LenneMGDietzePRumboldGRRedmanJRTriggsTJThe effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated drivingDrug Alcohol Depend2003722712781:CAS:528:DC%2BD3sXpt1ektr8%3D10.1016/j.drugalcdep.2003.08.002 – reference: ToriMELarochelleMRNaimiTSAlcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017JAMA Netw Open20203e20236110.1001/jamanetworkopen.2020.2361 – reference: HayleyACDowneyLAGreenMShiferawBKenneallyMKeaneMAdamsMShehabiYDriving simulator performance after administration of analgesic doses of ketamine with dexmedetomidine or fentanylJ Clin Psychopharmacol2019394464541:CAS:528:DC%2BC1MXhvFWlurnJ10.1097/JCP.0000000000001101 – reference: LinnoilaMHakkinenSEffects of diazepam and codeine, alone and in combination with alcohol, on simulated drivingClin Pharmacol Ther1974153683731:STN:280:DyaE2c7ktVeltQ%3D%3D10.1002/cpt1974154368 – reference: MartinCSEarleywineMMustyREPerrineMWSwiftRMDevelopment and validation of the biphasic alcohol effects scaleAlcohol Clin Exp Res19931711401461:STN:280:DyaK3s7pvV2muw%3D%3D10.1111/j.1530-0277.1993.tb00739.x – reference: National Center for Statistics and AnalysisAlcohol-impaired driving: 2018 data (Traffic Safety Facts. Report No. DOT HS 812 864)2019Washington, DCNational Highway Traffic Safety Administration – reference: American Pain Society. Pain management and dosing guide. 2016. http://americanpainsociety.org/uploads/education/PAMI_Pain_Mangement_and_Dosing_Guide_02282017.pdf – reference: ChihuriSLiGTrends in prescription opioids detected in fatally injured drivers in 6 US states: 1995-2015Am J Public Health20171071487149210.2105/AJPH.2017.303902 – reference: HedlundJMacekKDrug-impaired driving: marijuana and opioids raise critical issues for states2018Washington, DCGovernor’s Highway Safety Associationhttps://www.ghsa.org/resources/DUID18 – reference: KirkpatrickMGde WitHIn the company of others: social factors alter acute alcohol effectsPsychopharmacology (Berl)20132302152261:CAS:528:DC%2BC3sXot1Ojt70%3D10.1007/s00213-013-3147-0 – reference: RushCRPretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humansAlcohol Clin Exp Res2001259171:CAS:528:DC%2BD3MXjtFGmur0%3D11198720 – reference: IrwinCIudakhinaEDesbrowBMcCartneyDEffects of acute alcohol consumption on measures of simulated driving: a systematic review and meta-analysisAccid Anal Prev201710224826610.1016/j.aap.2017.03.001 – reference: ChihuriSLiGUse of prescription opioids and initiation of fatal 2-vehicle crashesJAMA Netw Open20192e18808110.1001/jamanetworkopen.2018.8081 – reference: StrandMCArnestadMFjeldBMorlandJAcute impairing effects of morphine related to driving: a systematic review of experimental studies to define blood morphine concentrations related to impairment in opioid-naive subjectsTraffic Inj Prev20171878879410.1080/15389588.2017.1326595 – reference: YadavAKVelagaNRLaboratory analysis of driving behavior and self-perceived physiological impairment at 0.03%, 0.05% and 0.08% blood alcohol concentrationsDrug Alcohol Depend20192051076301:CAS:528:DC%2BC1MXitVSqtLfK10.1016/j.drugalcdep.2019.107630 – reference: KingACMcNamaraPJHasinDSCaoDAlcohol challenge responses predict future alcohol use disorder symptoms: a 6-year prospective studyBiol Psychiatry20147579880610.1016/j.biopsych.2013.08.001 – reference: BabalonisSLofwallMRNuzzoPASiegelAJWalshSLAbuse liability and reinforcing efficacy of oral tramadol in humansDrug Alcohol Depend20131291-21161241:CAS:528:DC%2BC38XhsFKnsLzE10.1016/j.drugalcdep.2012.09.018 – reference: SetnikBSokolowskaMJohnsonFOldenhofJRomachMEvaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participantsHum Psychopharmacol2014292512651:CAS:528:DC%2BC2cXmsVGks7k%3D10.1002/hup.2394 – reference: ChihuriSLiGUse of prescription opioids and motor vehicle crashes: a meta analysisAccid Anal Prev201710912313110.1016/j.aap.2017.10.004 – reference: KingACde WitHMcNamaraPJCaoDRewarding, stimulant, and sedative alcohol responses and relationship to future binge drinkingArch Gen Psychiatry20116838939910.1001/archgenpsychiatry.2011.26 – reference: BerningAComptonRWochingerKResults of the 2013–2014 National Roadside Survey of alcohol and drug use by drivers. Traffic Safety Facts Research Note. Report No. DOT HS 812 1182015Washington, DCNational Highway Traffic Safety Administration – reference: KingACCaoDde WitHO’ConnorSJHasinDSThe role of alcohol response phenotypes in the risk for alcohol use disorderBr J Psych20195e38131:CAS:528:DC%2BC1MXisVaiur7J – reference: ZacnyJPGutierrezSSubjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteersPsychopharmacology (Berl)20112184714811:CAS:528:DC%2BC3MXmtlelsLk%3D10.1007/s00213-011-2349-6 – reference: LaceyJHKelley-BakerTBerningARomanoERamirezAYaoJMooreCBrainardKCarrKPellKComptonRDrug and alcohol crash risk: a case-control study (Report No. DOT HS 812 355)2016Washington, DCNational Highway Traffic Safety Administration – reference: BernhoftIMHelsTLyckegaardAHouwingSVerstraeteAGPrevalence and risk of injury in Europe by driving with alcohol, illicit drugs and medicinesProcedia Soc Behav Sci2012482907291610.1016/j.sbspro.2012.06.1259 – volume-title: Drug and alcohol crash risk: a case-control study (Report No. DOT HS 812 355) year: 2016 ident: 5702_CR23 – volume: 15 start-page: 368 year: 1974 ident: 5702_CR25 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1974154368 – volume: 55 start-page: 1332 issue: 12 year: 2015 ident: 5702_CR3 publication-title: J Clin Pharmacol doi: 10.1002/jcph.557 – volume: 32 start-page: 786 year: 2018 ident: 5702_CR11 publication-title: Palliat Med doi: 10.1177/0269216317746583 – volume: 75 start-page: 798 year: 2014 ident: 5702_CR19 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2013.08.001 – volume: 18 start-page: 788 year: 2017 ident: 5702_CR33 publication-title: Traffic Inj Prev doi: 10.1080/15389588.2017.1326595 – volume: 205 start-page: 107630 year: 2019 ident: 5702_CR37 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2019.107630 – volume: 29 start-page: 251 year: 2014 ident: 5702_CR32 publication-title: Hum Psychopharmacol doi: 10.1002/hup.2394 – volume-title: Results of the 2013–2014 National Roadside Survey of alcohol and drug use by drivers. Traffic Safety Facts Research Note. Report No. DOT HS 812 118 year: 2015 ident: 5702_CR5 – volume: 19 start-page: 200 year: 2000 ident: 5702_CR13 publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(99)00158-X – ident: 5702_CR29 – volume: 102 start-page: 248 year: 2017 ident: 5702_CR16 publication-title: Accid Anal Prev doi: 10.1016/j.aap.2017.03.001 – volume: 48 start-page: 2907 year: 2012 ident: 5702_CR4 publication-title: Procedia Soc Behav Sci doi: 10.1016/j.sbspro.2012.06.1259 – volume: 5 start-page: 1 issue: e38 year: 2019 ident: 5702_CR20 publication-title: Br J Psych – volume-title: Drug-impaired driving: marijuana and opioids raise critical issues for states year: 2018 ident: 5702_CR15 – volume: 133 start-page: 371 year: 1961 ident: 5702_CR12 publication-title: J Pharmacol Exp Ther – volume: 107 start-page: 1487 year: 2017 ident: 5702_CR8 publication-title: Am J Public Health doi: 10.2105/AJPH.2017.303902 – volume: 25 start-page: 9 year: 2001 ident: 5702_CR31 publication-title: Alcohol Clin Exp Res – ident: 5702_CR1 – volume: 19 start-page: S97 year: 2018 ident: 5702_CR6 publication-title: Traffic Inj Prev doi: 10.1080/15389588.2017.1378814 – volume: 89 start-page: 31 year: 2016 ident: 5702_CR17 publication-title: Accid Anal Prev doi: 10.1016/j.aap.2016.01.001 – volume: 9 start-page: 817 year: 2015 ident: 5702_CR27 publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S77978 – volume: 218 start-page: 471 year: 2011 ident: 5702_CR38 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-011-2349-6 – volume: 39 start-page: 446 year: 2019 ident: 5702_CR14 publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0000000000001101 – volume: 72 start-page: 271 year: 2003 ident: 5702_CR24 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2003.08.002 – volume: 3 start-page: e202361 year: 2020 ident: 5702_CR35 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.2361 – volume: 57 start-page: 197 year: 2019 ident: 5702_CR10 publication-title: Am J Prev Med doi: 10.1016/j.amepre.2019.02.025 – volume: 230 start-page: 215 year: 2013 ident: 5702_CR21 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-013-3147-0 – volume: 15 start-page: 409 year: 2011 ident: 5702_CR30 publication-title: Eur J Pain doi: 10.1016/j.ejpain.2010.09.008 – volume: 109 start-page: 123 year: 2017 ident: 5702_CR7 publication-title: Accid Anal Prev doi: 10.1016/j.aap.2017.10.004 – volume: 129 start-page: 116 issue: 1-2 year: 2013 ident: 5702_CR2 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2012.09.018 – volume: 85 start-page: 442 year: 2019 ident: 5702_CR34 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13818 – volume: 68 start-page: 389 year: 2011 ident: 5702_CR18 publication-title: Arch Gen Psychiatry doi: 10.1001/archgenpsychiatry.2011.26 – volume: 9 start-page: 141 year: 2005 ident: 5702_CR22 publication-title: Eur J Pain doi: 10.1016/j.ejpain.2004.05.010 – volume: 98 start-page: 191 year: 2008 ident: 5702_CR36 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2008.05.007 – volume-title: Alcohol-impaired driving: 2018 data (Traffic Safety Facts. Report No. DOT HS 812 864) year: 2019 ident: 5702_CR28 – volume: 17 start-page: 140 issue: 1 year: 1993 ident: 5702_CR26 publication-title: Alcohol Clin Exp Res doi: 10.1111/j.1530-0277.1993.tb00739.x – volume: 2 start-page: e188081 year: 2019 ident: 5702_CR9 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2018.8081 |
| SSID | ssj0000484 ssj0068394 |
| Score | 2.3777354 |
| Snippet | Rationale
Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are... Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are limited... Rationale Epidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are... RationaleEpidemiological data indicate that drivers testing positive for an opioid drug are twice as likely to cause a fatal car crash; however, there are... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 539 |
| SubjectTerms | Acuity Adult Alcohol Alcohols Analysis Biomedical and Life Sciences Biomedicine Blindness Cross-Over Studies Dose-Response Relationship, Drug Double-Blind Method Driving ability Driving Under the Influence - psychology Drug dosages Drug Synergism Drunk driving Epidemiology Ethanol - administration & dosage Ethanol - adverse effects Evaluation Female Humans Male Models, Psychological Narcotics Neurosciences Opioid-Related Disorders - psychology Opioids Original Investigation Oxycodone Oxycodone - administration & dosage Oxycodone - adverse effects Pharmacology/Toxicology Placebos Psychiatry Psychomotor Performance - drug effects |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fi9QwEB_0BPFF9PxXPSWCnA9uoW2StnlcxOMQTu7hFu6tZJMUF87use1y9kk_hJ_QT-JM-mftooJvLZmE0JlkZjozvwF4Izmq5aUqQ5tHMhSxjsLcxXGYuVTk1Hvb-v8dZ5_S04X4eCkv-6Kwesh2H0KS_qYei91IHVHMkYK3GZ7jm9twR5LvjlK8SOa7-1dQ6WX3kqL-74CYOZWRybyvm_nzghPdtH9D_6ai9tMn92KoXjWdPID7vU3J5p0QPIRbrjqEu2d91PwQjs87fOp2xi525Vb1jB2z8x1ydfsIvs3NtnFMTwB12bpk66-tQf-1cjOmu566-FBZ5sMMDL8f-tc9ccXq1RfqCeYss5sV_a_4-f3H9cZd-f5hm5attw3OcDVbVawrw2yZhwGpH8Pi5MPF-9Ow79AQGiniJlTl0gpdGsldqjhaVqkwVqJTxk2ZaZPYzKD9qHDURbFGU8gII6xapsJqND5y_gQOKtz8M2BoOySxloaXPBIoWEoLrXIb2digy6VMAPHAm8L08OXUReOqGIGXPT8L5Gfh-VncBPBunHPdgXf8k_otsbygk40rG90XKOD-CCOrmKPkiowM1ACOJpR4Is10eBCaor8R6iIRubcvlQrg9ThMMynLrXLrLdFIgrtPUxHA007Gxn1zHqcqiXgA2UT6RgLCCZ-OVKvPHi88yyUuituaDXK629bfP8fz_yN_AfcSSvfxCe1HcNBstu4l2mvN8pU_nr8AqRc3bA priority: 102 providerName: Springer Nature |
| Title | Acute administration of oxycodone, alcohol, and their combination on simulated driving—preliminary outcomes in healthy adults |
| URI | https://link.springer.com/article/10.1007/s00213-020-05702-w https://www.ncbi.nlm.nih.gov/pubmed/33169203 https://www.proquest.com/docview/2480025699 https://www.proquest.com/docview/2459355664 https://pubmed.ncbi.nlm.nih.gov/PMC7855562 |
| Volume | 238 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgkxAvCMa_jDEZCY0HGpHEzh8_oRa1TKBVFVql8hS5tiMqjbRrUo0-wYfgE_JJuHPcllRiT0lkO7rE57uz7-53hLyOGajlqSh8nQWxz0MZ-JkJQz81Cc-w9ra25x0Xw-R8zD9N4ok7cKtcWOVGJlpBrecKz8jfRTyz-lmI94trH6tGoXfVldC4Sw4RugxDutJJupPEHJMwm4cELIEGkplhQlmcuQwam0eHmg7dmegXTkFE3LS01L6s_kdZ7QdS7nlTrZIaPCQPnHVJuw07PCJ3THlE7l04__kRORs1SNXrDr3cJV5VHXpGRzsM6_Vj8rOrVrWhsgWtS-cFnf9YK9jJlqZDZVNdF25KTa3DgcKvhJ2261zSavYdq4MZTfVyhicXf379XizNla0ktlzT-aqGEaais5I2CZlragFBqidkPOhffjj3Xa0GX8U8rH1RTDWXhYqZSQQDGyvhSsewPWOqSKWKdKrAkhTQaoJQglGkuOJaTBOuJZghGXtKDkog_jmhYEVEoYwVK1jAgcWE5FJkOtChgs2XUB4JN3OTKwdkjvU0rvItBLOdzxzmM7fzmd945O12zKKB8bi19xuc8hzXOLxZSZeqAPQhWlbeBR7mKZqqHjlp9YS1qdrNG6bJnWyo8h0ne-TVthlHYrxbaeYr7BMj8H2ScI88a3hsSzdjYSKigHkkbXHftgMihrdbytk3ixyeZjG8FMjqbPh0R9b_f8fx7V_xgtyPMNDHhrKfkIN6uTIvwVKrp6d2OZ6Sw-6g1xvi9ePXz3249vrD0RdoHUfdv3l-P74 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIuCMrLUGCRoByIhe1dvw4IBWiV0iaKUCv15jq7axGpOCEPBZ_gR_A7-FH8EmbWdoIj0VtviXZ2tcnMzmNn5xuAFz5HszyMM1tFjm8LN3XsSLuuHepARNR7W5n7jl4_6J6KT2f-2Rb8rmth6FllrRONolZjSXfkbzwRGfscx-8m32zqGkXZ1bqFRikWR7pYYsg2e3v4Efn70vMO9k8-dO2qq4AtfeHO7TgbKpFm0uc6iDl6A4GQysdAgsssTKWnQok-T4yj2nFTNN9SSKHiYSBUigYz4rjuNdgWHEOZFmy_3-8PPq91v6Cyz_JLgL5HCQLNqYTNj6qaHVO5R7aVEqiUiQ5RKS0bdnHTOvxjHjefbm7kb41ZPLgNtyp_lnVKAbwDWzrfgeu9KmO_A3uDEhu7aLOTdanXrM322GCNml3chR8duZhrljbAfNk4Y-PvhcTYOddtlpb9fPFDrphJcTBkHsb2FXHOZqOv1I9MK6amI7or-fPz12SqL0zvsmnBxos5ztAzNspZWQJaMANBMrsHp1fCx_vQynHzD4Gh3-K5qS95xh2BQh2nIo0j5ShXYrgXSwvcmjeJrKDTqYPHRbICfTb8TJCfieFnsrTg9WrOpAQOuZT6FbE8Ia2CK8u0Ko7A_RE-V9LBUyNCco4t2G1QojaQzeFaaJJKG82S9dmx4PlqmGbSC7tcjxdE4xPUfhAICx6UMrbaN-duEHsOtyBsSN-KgDDKmyP56IvBKg8jHxfFbbVrOV1v6_9_x6PLf8UzuNE96R0nx4f9o8dw06NnRuYh_S605tOFfoJ-4nz4tDqcDM6vWh_8BcSoeC4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIlVcEJSXocAiQTkQq7Z3_dgDQhElaimtcmil3Mxmdy0iFTvEiYJP8CP4NfwcfgkzazvBkeitt0T70CYzO4-dmW8IeRkyUMtjkbk68UKX-9JzE-P7bmwinmDvbW3fO07PoqML_nEUjrbI77YWBtMqW5loBbUuFL6RHwQ8sfpZiIOsSYsYHg7eTb-52EEKI61tO42aRU5MtQT3rXx7fAi0fhUEgw_n74_cpsOAq0Luz12RjTWXmQqZiQQDyyDiSofgVDCVxVIFOlZg_wgYNZ4vQZUrrrgW44hrCcozYbDvDXIzZqGPdywexWstwLEAtP4SgRVSw0EzLGYLk6Z6x9bwoZbFUCrGpGMQT8uOhtzUE_8oys0kzo1IrlWQgzvkdmPZ0n7NinfJlsl3yc5pE7vfJfvDGiW76tHzddFX2aP7dLjGz67ukR99tZgbKjuwvrTIaPG9UuBF56ZHZd3ZFz7kmtpgBwUygpffTM5pOfmKncmMpno2wVeTPz9_TWfm0nYxm1W0WMxhhSnpJKd1MWhFLRhJeZ9cXAsVH5DtHA7_iFCwYAJfhoplzOPA3kJyKRLtaV-B4yeUQ_yWNqlqQNSxl8dluoJ_tvRMgZ6ppWe6dMib1ZppDSFy5ezXSPIU5QvsrGRTJgHnQ6SutA_3h8doJjtkrzMT5ILqDrdMkzZyqUzXt8ghL1bDuBJz7XJTLHBOiKD7UcQd8rDmsdW5GfMjEXjMIXGH-1YTEK28O5JPvljU8jgJYVM4Vq_l0_Wx_v93PL76VzwnOyAF0k_HZydPyK0A841sRv0e2Z7PFuYpGIzz8TN7Myn5fN2i4C8b73r- |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+administration+of+oxycodone%2C+alcohol%2C+and+their+combination+on+simulated+driving%E2%80%94preliminary+outcomes+in+healthy+adults&rft.jtitle=Psychopharmacology&rft.au=Babalonis%2C+Shanna&rft.au=Coe%2C+Marion+A.&rft.au=Nuzzo%2C+Paul+A.&rft.au=Lofwall%2C+Michelle+R.&rft.date=2021-02-01&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=238&rft.issue=2&rft.spage=539&rft.epage=549&rft_id=info:doi/10.1007%2Fs00213-020-05702-w&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00213_020_05702_w |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |